The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A16 | Other alimentary tract and metabolism products | |
| 3 | A16A | Other alimentary tract and metabolism products | |
| 4 | A16AX | Various alimentary tract and metabolism products | |
| 5 | A16AX18 |
| Active Ingredient | Description | |
|---|---|---|
| Lumasiran |
Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) that reduces levels of glycolate oxidase (GO). Decreased GO enzyme levels reduce the amount of available glyoxylate, a substrate for oxalate production. This results in reduction of urinary and plasma oxalate levels, the underlying cause of disease manifestations in patients with primary hyperoxaluria type 1 (PH1). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| OXLUMO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
